The Announcement
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that 14 previously restricted peptides would return to Category 1 status. The announcement was made on the Joe Rogan Experience podcast — notably not through an official FDA or HHS regulatory channel. This is the most significant regulatory shift in the peptide market in years. As of early April 2026, formal rulemaking is still in progress — check FDA.gov for the latest status.
What Are the 14 Peptides?
The peptides slated for reclassification include:
- BPC-157 — Body Protection Compound, widely used for tissue repair research
- TB-500 (Thymosin Beta-4 fragment) — Recovery and healing peptide
- CJC-1295 — Growth hormone releasing hormone analog
- Ipamorelin — Growth hormone secretagogue
- Thymosin Alpha-1 — Immune modulation peptide
- AOD-9604 — Fat metabolism peptide fragment
- GHK-Cu — Copper peptide for tissue remodeling
- Selank — Anxiolytic peptide
- Semax — Nootropic peptide
- MOTS-c — Mitochondrial peptide
- KPV — Anti-inflammatory tripeptide
- Kisspeptin-10 — Reproductive hormone peptide
- Epithalon — Telomerase-activating peptide
- DSIP — Delta sleep-inducing peptide
These peptides were moved to Category 2 ("Substances with Safety Concerns") by the FDA in late 2023, effectively prohibiting their compounding by pharmacies. The announced reclassification is intended to reverse that decision.
What Category 1 Means
Category 1 status means these peptides can be legally compounded by licensed pharmacies with a valid physician prescription. Prior to this change, many of these peptides were in regulatory gray areas that restricted pharmacy compounding.
Impact on the Market
For Consumers
- More legal options: Obtain these peptides through licensed compounding pharmacies with a prescription
- Better quality assurance: Pharmacy-compounded peptides must meet USP standards
- Insurance considerations: While unlikely to be covered initially, the legal pathway is clearer
For the Gray Market
- Research vendors will continue to operate under "for research use only" labeling
- Increased competition from pharmacies may drive quality improvements
- Some users may transition to pharmacy sources for legal protection
For Clinicians
- Clearer legal framework for prescribing peptide therapy
- More pharmacy options for sourcing compounded peptides
- Growing patient demand as awareness increases
What Hasn't Changed
- Research peptides sold "for research use only" remain in their current legal status
- A valid prescription is still required for pharmacy-compounded peptides
- The reclassification has been announced but formal rulemaking is still in progress — check FDA.gov for the latest
What to Do Now
- If you're currently using gray market peptides, consider establishing a relationship with a peptide-knowledgeable healthcare provider
- Research compounding pharmacies in your state
- Stay informed — the regulatory landscape is evolving rapidly